4Verstappen S M M,Jacobs J W G,Van der Veen M J,et a1.Intensive treatment with methotrexate in early rheumatoid arthritis:aiming for remission.Computer Assisted Management in Early RheumatoidArthritis(CAMERA.an open-label strategy trial)[J].AnnRheum Dis,2007,66(11):1443-1449.
5Van Dongen H,Van Aken J,Lard L I L,et a1.Efficacy of methotrexate treatment in patients with probable rheum atoidarthritis:adouble-blind,randomized,placebo-controlled trial[J].Arthritis Rheum,2007,56(5):1424-1432.
6Braun J,kaslner P,Flaxenberg P,et a1.Comparison of the Clinical efficacy and safety of subcutaneous vergus oral administrationof methotrexate in patients with active rheumatoid arthritis:resuits of a six-month,multicenter,randomized,double-blind,controlled,phaseⅣtrial.Arthritis Rheum,2008,58(1):73-81.
7Kremer J M,Genovese M C,Grant W,el a1.Concomitant leflunomide therapy in patients with active rheumatoid arthritis despitestable doses of methortexate[J].Ann Intem Med,2002,137(9):726-733.
8Smolen JS,Nash P,Durez P,et al.Maintenance,reduc-tion,or withdrawal of etanercept after treatment with et-anercept and methotrexate in patients with moderaterheumatoid arthritis(PRESERVE): a randomised con-trolled trial[J].Lancet,2013,381(9870):918-929.
9Takeuchi T,Matsubara T,Nitobe T,et al.Erratum to:phase Ⅱ dose-response study of abatacept in Japanesepatients with active rheumatoid arthritis with an inade-quate response to methotrexate[J].Mod Rheumatol,2013,23(2):236-237.
10van der Heijde D,Tanaka Y,Fleischmann R,et al.Tofac-itinib(CP-690,550)in patients with rheumatoid arthritisreceiving methotrexate:twelve-month data from a twenty-four-month phase Ⅲ randomized radiographic study[J].Arthritis Rheum,2013,65(3):559-570.
